Professor Sir Jonathan Van-Tam emphasized that COVID-19 remains a public health concern similar to seasonal flu, particularly for vulnerable populations.
2
The introduction of Sanofi's Nuvaxovid vaccine adds a protein-based option to the UK's vaccination program, complementing existing mRNA vaccines.
3
Van-Tam noted that the lethality of COVID-19 has decreased, aligning more closely with seasonal flu due to vaccination and less lethal variants.
4
He highlighted the importance of having diverse vaccine technologies available for future pandemics, as no single technology can be guaranteed to work.
5
The addition of Nuvaxovid presents a research opportunity to explore the effects of alternating vaccine types on long-term immunity.
